| Lumina Llc | |
|
353 Route 10 Ste 101 Mangilao GU 96913-1392 | |
| (671) 969-4242 | |
| Not Available |
| Full Name | Lumina Llc |
|---|---|
| Speciality | Clinic/center - Dental |
| Location | 353 Route 10 Ste 101, Mangilao, Guam |
| Authorized Official Name and Position | Sarah Lee Clegg (OWNER) |
| Authorized Official Contact | 5102833460 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Lumina Llc Po Box 9868 Tamuning GU 96931-5868 Ph: (510) 283-3460 | Lumina Llc 353 Route 10 Ste 101 Mangilao GU 96913-1392 Ph: (671) 969-4242 |
| NPI Number | 1003418369 |
|---|---|
| Provider Enumeration Date | 11/12/2020 |
| Last Update Date | 11/13/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003418369 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QD0000X | Clinic/center - Dental | (* (Not Available)) | Primary |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral delivery systems, today announced that Oramed entered into a Manufacturing Supply Agreement with sanofi-aventis. According to the MSA, sanofi-aventis will supply Oramed with specified quantities of recombinant human insulin to be used by Oramed for its clinical trials in the USA.
BioTime, Inc. today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 million investment by private investors and a $1.5 million investment from BioTime that valued ReCyte Therapeutics at a post money valuation of $60 million on a fully diluted basis.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that National Government Services has issued a positive coverage decision for Posterior Tibial Nerve Stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence associated with overactive bladder (OAB). Coverage for the proprietary Urgent PC device was effective August 10, 2014.
Having your healthcare professional prescribe you a dose of bench presses to ward off an infection or help heal an injury may sound like shonky healthcare but could actually be the advice of the near future, according to Griffith University scientists.
› Verified 2 days ago